Sarepta Therapeutics, Inc.'s SEC filings document an operating biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under SRPT. Form 8-K reports furnish quarterly and annual financial results, product revenue disclosures for ELEVIDYS and PMO therapies, and clinical or regulatory updates for Duchenne muscular dystrophy treatments and siRNA pipeline programs.
Other filings cover proxy governance, executive compensation, equity-award plans and leadership-transition disclosures. Material-event reports also describe capital-structure actions, including exchange agreements for convertible senior notes, issuance of new convertible notes, common stock consideration and related indenture terms.
Sarepta Therapeutics director Stephen Mayo reported an open-market sale of 7,239 shares of common stock at $17.02 per share. According to the footnote, this sale was made to generate cash to pay taxes arising from the vesting of restricted stock unit awards, indicating a tax-driven transaction rather than a discretionary portfolio move. After the sale, Mayo directly held 1,765 Sarepta shares.
Sarepta Therapeutics, Inc. executive Cristin Rothfuss, EVP and General Counsel, reported a routine tax-related share disposition. On March 11, 2026, the company withheld 974 shares of common stock at $17.03 per share to satisfy tax obligations from restricted stock units that vested on March 10, 2025.
After this withholding, Rothfuss directly holds 137,544 shares of Sarepta common stock, so the transaction represents only a small portion of her overall position and does not reflect an open-market sale.
Form 144 notice: A reporting person submitted a notice to sell restricted Common Stock of SRPT.
The filing lists proposed sale lots with dates and share counts: 03/10/2026 2,383 shares; 03/01/2025 1,846 shares; 11/16/2024 1,431 shares; 03/06/2024 961 shares; 11/16/2022 572 shares; and 11/16/2023 46 shares.
Sarepta Therapeutics, Inc. Chief Financial Officer Ryan Ho-Yan Wong reported routine share dispositions tied to tax withholding on restricted stock unit vesting. On March 9, 2026, a total of 275 shares of common stock were withheld by the company to cover tax obligations from RSUs granted in 2022 and 2023. Following these tax-withholding events, Wong directly holds 135,320 shares of Sarepta common stock, so the withheld amount represents a modest adjustment to his overall equity position rather than an open-market sale.
Sarepta Therapeutics, Inc. executive vice president and general counsel Cristin Rothfuss reported routine share dispositions related to tax withholding. The company withheld a total of 830 shares of common stock at $16.95 per share to cover tax obligations on restricted stock units that vested from grants dated March 7, 2022 and March 6, 2023. Following these tax-withholding entries, Rothfuss directly holds 138,518 shares of Sarepta common stock.
Sarepta Therapeutics, Inc. executive Louise Rodino-Klapac, President of R&D and Tech Ops, reported routine tax-related share dispositions. On March 9, 2026, a total of 1,399 shares of common stock were withheld by the company at $16.95 per share to cover tax obligations on vesting restricted stock units granted in 2022 and 2023. After these withholdings, she directly holds 226,271 shares of Sarepta common stock.
Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan reported routine share dispositions tied to tax withholding rather than open-market sales. On March 9, 2026, a total of 1,619 shares of common stock were withheld by the company at $16.95 per share to cover tax obligations from vesting restricted stock units granted on March 7, 2022 and March 6, 2023. After these transactions, Estepan directly owned 203,080 shares of Sarepta common stock.
Sarepta Therapeutics EVP and General Counsel Cristin Rothfuss reported a small share disposition for tax withholding purposes. On March 2, 2026, 408 shares of Sarepta common stock were withheld by the company at $16.20 per share to cover taxes on restricted stock units that vested from a grant made on March 1, 2024. After this tax-withholding transaction, Rothfuss’s directly held ownership stood at 139,348 shares of common stock.
Sarepta Therapeutics, Inc. Chief Financial Officer Ryan Ho-Yan Wong reported a tax-related share disposition linked to restricted stock vesting. On March 2, 2026, 450 shares of common stock were withheld by the company at $16.20 per share to cover tax withholding obligations from restricted stock units granted on March 1, 2024. After this withholding transaction, Wong directly owned 135,595 shares of Sarepta common stock.
Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan reported equity award activity tied to prior grants. On March 1, 2026, 8,125 Performance Stock Units earned under a March 1, 2024 award were converted into 8,125 shares of common stock as they vested based on milestone achievement.
To cover tax withholding on the vesting of this PSU award and related restricted stock units, the company withheld a total of 4,176 shares of common stock on March 2, 2026, valued at $16.20 per share, as tax-withholding dispositions. After these non‑market transactions, Estepan directly owned 204,699 common shares.